ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

NCI Relates FDA Instructions On Latest IND Delays

October 29, 1976

No Evidence Of Fraud Found In NCI Audit Of NSABP Trials

April 29, 1994

Researchers Feel Impact of Shutdown As Grant Review Stops, Funding Runs Dry

January 5, 1996

Agriculture Dept. Asks clearinghouse To Consider Broader Risk Assessment Data

July 14, 1978

Ten-Year Breast Cancer Survival Improved In Past 60 Years, MD Anderson Study Finds

October 29, 2010

Flexibility OK In Paying Grants If Justified, Upton Affirms

September 1, 1978